Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025
February 26, 2025 | 06:45
Everest Medicines, today announced the presentation of maintenance data from its multi-center Phase III clinical study of etrasimod (VELSIPITY®) in Asia at the 20th European Crohn's and Colitis Organization Congress (ECCO 2025).
Mobile Version
